Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that it will release its 2014 fourth quarter and year-end financial results on Wednesday, December 17, 2014, before the market opens.
Scott Tarriff, President and Chief Executive Officer, and David E. Riggs, Chief Financial Officer, will host a conference call to discuss the results as follows:
|Date:||Wednesday, December 17, 2014|
|Time:||8:30 a.m. Eastern Standard Time|
|Telephone access:||866-952-1906 (US)
A replay of the conference call will be available for one week after the call's completion by dialing 800-283-4799 (US) or 402-220-0860 (International) and entering conference call ID EGRXQ414. The webcast will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. The Company’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
In-Site Communications, Inc.
Lisa M. Wilson, 212-452-2793